Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
|Slideshows|September 5, 2019
Psychiatry Roundup: 7 New Developments in Depression
Author(s)Leo Robert
Neurotransmitters may enhance mood-boosting effectS of exercise, cigarette use abstinence efforts going up in smoke, and other recent findings are summarized here.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Psychiatric Times
1
What Clinicians Need to Know About Postpartum Psychosis
2
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
3
Brain Trust: Therapeutic Drug Monitoring and Adherence in Schizophrenia, With Jonathan M. Meyer, MD
4
AI as a Task-Replacing Tool for Psychiatric Care: A Conversation With Christoph Correll, MD
5